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ABSTRACT
Background We sought to investigate the diagnostic
yield and mutation spectrum in previously reported
genes for early-onset epilepsy and disorders of severe
developmental delay.
Methods In 400 patients with these disorders with no
known underlying aetiology and no major structural
brain anomaly, we analysed 46 genes using a
combination of targeted sequencing on an Illumina
MiSeq platform and targeted, exon-level microarray copy
number analysis.
Results We identiﬁed causative mutations in 71/400
patients (18%). The diagnostic rate was highest among
those with seizure onset within the ﬁrst two months of
life (39%), although overall it was similar in those with
and without seizures. The most frequently mutated gene
was SCN2A (11 patients, 3%). Other recurrently
mutated genes included CDKL5, KCNQ2, SCN8A (six
patients each), FOXG1, MECP2, SCN1A, STXBP1 (ﬁve
patients each), KCNT1, PCDH19, TCF4 (three patients
each) and ATP1A3, PRRT2 and SLC9A6 (two patients
each). Mutations in EHMT1, GABRB3, LGI1, MBD5,
PIGA, UBE3A and ZEB2 were each found in single
patients. We found mutations in a number of genes in
patients where either the electroclinical features or
dysmorphic phenotypes were atypical for the identiﬁed
gene. In only 11 cases (15%) had the clinician sufﬁcient
certainty to specify the mutated gene as the likely cause
before testing.
Conclusions Our data demonstrate the considerable
utility of a gene panel approach in the diagnosis of
patients with early-onset epilepsy and severe
developmental delay disorders., They provide further
insights into the phenotypic spectrum and genotype–
phenotype correlations for a number of the causative
genes and emphasise the value of exon-level copy
number testing in their analysis.
INTRODUCTION
Seizures affect approximately 7 in 10 000 children
before the age of 2 years and 1 in 500 before
5 years and are often associated with developmen-
tal delay.1–3 An increasing number of causative
genes are recognised in what is emerging as an
overlapping group of disorders with varying preva-
lence and severity of seizures, developmental delay
and, in some cases, dysmorphic features or con-
genital malformations.4 5
Standard diagnostic approaches include biochem-
ical and enzyme analysis for neurometabolic disor-
ders, MRI brain imaging and genome-wide
microarray analysis.1 Where these investigations do
not identify a structural brain anomaly, biomarkers
for a neurometabolic disorder, or chromosomal
CNV, diagnosis is often challenging and has trad-
itionally been dependent on the recognition of a
characteristic phenotype followed by targeted
single-gene testing. Examples include
SCN1A-related seizure disorders and classical Rett
syndrome (MECP2).6 7
With increasing published literature on the wide
spectrum of molecular aetiologies in these patients,
targeted gene testing has allowed diagnosis in an
increasing number of patients. Children with
early-onset seizures and severe developmental delay
(early infantile epileptic encephalopathy (EIEE))
can often be classiﬁed according to their electrocli-
nical phenotype, for example, Ohtahara syndrome,
West syndrome and epilepsy of infancy with migrat-
ing focal seizures (EIMFS).8 For some cases, accur-
ate EIEE syndrome classiﬁcation can assist in the
identiﬁcation of causative genes. Similarly, the rec-
ognition of a number of neurobehavioural and dys-
morphic syndromes also helps identify
disease-causing genes in some individuals.9
However, for many cases, clinical prediction of
causative genes is challenging due to genetic hetero-
geneity, phenotypic pleiotropy, and for some
patients, the phenotype is not sufﬁciently distinct-
ive to accurately predict the causative gene. In such
cases, sequential single-gene testing is time-
consuming, costly and often unsuccessful.
With the increasing availability of next-
generation sequencing technologies, it is becoming
possible to rely less on targeted single-gene ana-
lysis. This has the potential to improve diagnostic
rates. It can also clarify and broaden the phenotypic
spectrum of genes by reducing ascertainment
bias.10
We, therefore, chose to explore the diagnostic
utility and genotype–phenotype insights provided
by analysis of a panel of 46 genes in 400 patients
with early-onset seizures and/or severe develop-
mental delay.
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METHODS
Patients and samples
Four hundred patients with early-onset seizure disorders and/or
severe developmental delay were referred and consented for
gene panel testing by a paediatric neurologist or clinical geneti-
cist, from a number of tertiary centres in the UK. Recruited
patients did not have major structural brain malformations nor
clinically signiﬁcant copy number defects on microarray.
Standardised clinical information was collected using a pre-test
questionnaire completed by the recruiting clinician. Lymphocyte
DNAwas collected in all cases using standard procedures.
We selected genes for analysis in the panel that were estab-
lished causes of early-onset seizures and/or severe developmental
delay in patients without frequent major structural brain anomal-
ies. Genes leading to neurometabolic disorders with readily iden-
tiﬁable blood/urine/cerebrospinal ﬂuid (CSF) biomarkers were
not included in the panel. The genes analysed were ADSL,
ALG13, ARHGEF9, ARX, ATP1A3, ATRX, CDKL5, CHD2,
CHRNA4, CHRNB2, CNTNAP2, EHMT1, FOXG1, GABRB3,
GRIN2A, GRIN2B, KCNQ2, KCNT1, KIAA1279, LGI1, MAGI2,
MBD5, MECP2, MEF2C, NRXN1, PCDH19, PIGA, PLCB1,
PNKP, POLG, PRRT2, SCN1A, SCN2A, SCN8A, SLC16A2,
SLC25A22, SLC2A1, SLC9A6, SPTAN1, STXBP1, SYNGAP1,
TBC1D24, TCF4, UBE2A, UBE3A and ZEB2. We performed our
analyses over 18 months in three phases, adding newly discov-
ered genes to the panel as they were identiﬁed and employing
improved sequence capture technology as it became available
(see online supplementary table S1). In phase 1, 48 patients were
analysed through 29 genes. In phase 2, 94 patients were analysed
through 39 genes. In phase 3, 258 patients were analysed
through 46 genes (see online supplementary table S1). Patients in
phases 1 and 2 were not retested with later versions of the panel.
Sequence analysis
All patients were sequenced using a MiSeq platform (Illumina).
Parental DNA was only analysed to follow-up on potentially
pathogenic variants (described below). Phase 1 cases were ana-
lysed using the Haloplex sequence capture system (Agilent).
Phase 2 cases were analysed using the TrueSeq Custom Amplicon
(TSCA) system (Illumina), and the phase 3 cases were analysed
using the SureSelectXTsystem (Agilent). Sequence capture librar-
ies were designed to capture the full transcript of the target genes
plus 50 bps at each intron–exon boundary using the proprietary
design tools, respectively. Libraries were captured using the
standard protocols for each sequence capture system and sequen-
cing performed using standard protocols for the MiSeq platform.
Barcoding allowed multiplexing of 16 cases per ﬂow cell.
We analysed sequence data using an in-house pipeline.
Regions of interest were deﬁned in BED ﬁle format by upload-
ing human gene nomenclature committee (HGNC) genes names
to the UCSC table browser.11 Sequence reads in FASTQ format
were aligned to the reference human genome (hg19) using BWA
(0.6.1-r104) and default settings.12 Variant calling was per-
formed across the entire region of interest using VarScan2
(V.2.3.7) with the following settings: minimum 30× coverage,
minimum ﬁve alternate reads, minimum phred-like base-quality
of 20.13 14 Variant calls in VCF format were then annotated
using Ensembl Variant Effect Predictor (V.73) and the output
parsed using an in-house script, which converts the annotated
VCF ﬁle into Excel format for subsequent variant ﬁltering and
prioritisation.15 For each case, coverage was assessed across the
coding exons of the target genes and their intron–exon
boundaries (+6 bp and −12 bp) and expressed as the percentage
of bases covered at ≥30×.
We used Sanger sequencing to analyse the commonly mutated
GC-rich amplicon of the ARX gene that was not well targeted
by our next-generation assays.
We also Sanger sequenced custom-designed amplicons to
conﬁrm potentially disease-causing variants in probands and
perform segregation analysis in parental lymphocyte DNA
samples. We performed PCR using MegaMix (Microzone, UK),
puriﬁed PCR products using AmpureXP (Beckman Coulter, UK)
and sequenced them using Big Dye Terminator V.3.1 Cycle
Sequencing Kit (Applied Biosystems, USA). We used Mutation
Surveyor (SoftGenetics, USA) to align traces to the reference
sequence and call variants. Variant prioritisation and reporting
was performed as a joint clinical laboratory process to optimise
interpretation of both molecular and clinical data.
Copy number analysis
In 33 mutation negative cases from phase 1, we performed
exon-level copy number analysis using a custom Roche
Nimblegen oligonucleotide 135K aCGH (see online
supplementary table S1). Arrays were designed using proprietary
Nimblegen software and read using a Roche Nimblegen MS
200 scanner. We analysed array data using CGH Fusion
(infoQuant). We conﬁrmed copy number abnormalities and per-
formed segregation analysis in parental lymphocyte DNA
samples using multiplex ligation-dependent probe ampliﬁcation
(MLPA) and/or FISH.
RESULTS
We identiﬁed causative mutations in 71 patients (18%; see table 1,
online supplementary table S1 and ﬁgure 1). The most frequently
mutated gene was SCN2A (11 patients, 3%), occurring de novo in
all patients. Other recurrently mutated genes included CDKL5,
KCNQ2, SCN8A (six patients each), FOXG1, MECP2, SCN1A,
STXBP1 (ﬁve patients each), KCNT1, PCDH19, TCF4 (three
patients each) and ATP1A3, PRRT2 and SCL9A6 (two patients
each). Mutations in EHMT1, GABRB3, LGI1, MBD5, PIGA,
UBE3A and ZEB2 were each found in single patients. Of the 54
patients for whom parental samples were available, 51 mutations
were conﬁrmed as de novo. For two patients, both harbouring
KCNQ2 variants, mutations were inherited from a similarly
affected parent. One FOXG1 variant had been inherited from the
child’s mother, who was mosaic for the mutation and clinically
unaffected. Sixty-eight variants were either point mutations or
small insertions and deletions. Three were larger de novo copy
number abnormalities detected on our targeted array, a deletion
encompassing MBD5 and two other genes (conﬁrmed by FISH
using probe RP11-548K3), a single-exon deletion within MECP2
Table 1 Summary of the 400 patients analysed
Cases
Cases with
mutation
Percentage
with mutation (%)
All cases 400 71 18
Male 192 41 21
Female 208 29 14
Seizures 323 60 19
Seizure onset <2 years 222 31 14
Seizure onset <2 months 77 30 39
Developmental delay, no seizures 77 11 14
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and a multiexon duplication within CDKL5 (both conﬁrmed by
MLPA using kits P015-E1 and P189-B1, respectively).
Mutations were identiﬁed in patients with a broad range of
phenotypes including EIEE syndromes, Dravet syndrome, neo-
natal seizures and a range of severe developmental delay pheno-
types without seizures or with infrequent or resolved seizures
(see tables 1 and 2 and online supplementary table S2).
Mutations were identiﬁed in 60 of the 323 (18%) individuals
with seizures, including 30 of the 76 (39%) with seizure onset
under 2 months of age. Mutations were identiﬁed in 11 of the
77 (14%) without seizures.
Mean coverage varied substantially between platforms, with a
mean of 90.0% bases covered at ≥30× for samples analysed
using the Haloplex system, 85.0% bases for the TSCA system
and 99.8% for the SureSelect system.
DISCUSSION
Our panel detected clearly pathogenic mutations in 18% of our
cases, demonstrating its signiﬁcant diagnostic utility in patients
with early-onset seizure disorders and/or severe developmental
delay. This diagnostic rate is impressive given the large number
of previous investigations that many of the cases had undergone.
In many cases, this had included numerous sequential single-
gene testing.
Mutations were found in patients with a broad range of phe-
notypes (tables 1 and 2). The mutation detection rate was
similar in those with seizures (18%) and those without seizures
(14%). The mutation detection rate was highest among those
with early-onset seizures, before the age of 2 months (39%).
In only 11 cases (15%) had the clinician sufﬁcient clinical cer-
tainty to specify on the pre-test questionnaire the actual mutated
gene as the likely cause before genetic testing. These included
one patient with an ATP1A3 mutation, presenting with seizures,
developmental delay and alternating hemiplegia (case 1); two
with inherited KCNQ2 mutations, both presenting with
autosomal-dominant neonatal seizures (cases 20 and 21); one
with a KCNT1 mutation presenting with EIMFS (case 24); three
with MECP2 mutations presenting with classical Rett syndrome
(cases 27, 28 and 30); one with a PRRT2 mutation presenting
with kinesogenic dyskinesia (case 36); one with an SCN1A
mutation presenting with Dravet syndrome (case 39); one with
a TCF4 mutation presenting with dysmorphism characteristic of
Pitt–Hopkins syndrome (case 68); and one with a ZEB2 muta-
tion presenting with facial dysmorphism and congenital malfor-
mations characteristic of Mowat–Wilson syndrome (case 71).
However, it was clearly evident from analysis of the pre-test
clinical proforma that even among these, the clinician often con-
sidered a wider range of genes as possibly causative for their
patient’s clinical phenotype.
In many of the remaining cases, panel analysis provided a
diagnosis that would not otherwise have been reached using
conventional approaches or reduced the time, number of inves-
tigations and cost to make the diagnosis. In turn, this allowed
appropriate advice to be given on prognosis, the tailoring of
medical management (eg, antiepileptic medication considered
suitable for speciﬁc genotypes) and accurate advice on risks of
recurrence for future pregnancies.
In a number of cases, electroclinical diagnoses considered
strongly suggestive of the causative gene were only reached after
re-examination of the phenotype in the light of the identiﬁed
mutation. For example, we found a KCNT1 mutation in a child
later recognised to have classical EIMFS (case 23) rather than
the initial diagnosis of epileptic encephalopathy with multifocal
EEG discharges.
Similarly, in other cases, identiﬁcation of the causative muta-
tion allowed retrospective identiﬁcation of a dysmorphic syn-
drome that is often considered recognisable. We identiﬁed
MECP2 mutations in two children whose clinical features were
consistent with classical Rett syndrome but in whom it had not
been considered the most likely causative gene (cases 29 and
31). We identiﬁed TCF4 mutations in two children with severe
developmental delay and facial features later conﬁrmed to be in
keeping with Pitt–Hopkins syndrome (cases 67 and 69). We also
reported a UBE3A mutation in a child previously tested for
Angelman methylation defects but in whom a UBE3A mutation
was not considered sufﬁciently likely to warrant single-gene
mutation analysis of UBE3A (case 70).
The majority of mutations were found in cases where the
phenotype was either not easily distinguishable from that caused
by a number of other genes or was atypical for the previously
reported phenotype(s), emphasising the beneﬁt of a gene panel
approach over targeted single-gene testing. The extent to which
more detailed pre-test phenotyping could ameliorate this varies
between genes. Many of the patients described in this series had
undergone extensive clinical and electroclinical workup by
experts in these disorders prior to panel testing, illustrating the
challenges in recognising the causative gene based on
phenotype.
De novo monoallelic mutations in SCN2A are an increasingly
recognised cause of an early-onset seizure and developmental
delay.16 Despite its identiﬁcation in 2001, testing of the gene
has only become widely available with the advent of next-
generation sequencing.17 SCN2A was the most frequently
mutated gene in our series, accounting for 11 of 71 mutations
and 3% of the series overall (ﬁgure 1 and table 2). The majority
of mutations were de novo missense variants and occurred in
cases with EIEE and severe or profound developmental delay.
The median age of onset of seizures was 1 day of age (range
1 day to 2 years 11 months). The only child with a truncating
mutation in SCN2A (case 48) presented with autism and clusters
Figure 1 Number of cases with mutations in each gene.
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Table 2 Summary of the 71 mutation-positive cases
Case Gene Mutation Inheritance Gender Diagnosis at referral for testing Seizures
1* ATP1A3 het c.958G>A; p.(Ala320Thr) De novo M Possible ATP1A3-related disorder Yes
2 ATP1A3 het c.2839G>A; p.(Gly947Arg) Not in mother M Developmental delay with seizures Yes
3 CDKL5 hemi c.532C>T; p.(Arg178Trp) De novo M EIEE Yes
4 CDKL5 hemi c.2152G>A; p.(Val718Met) Unknown M EIEE Yes
5 CDKL5 hemi c.2177_2186delinsAATGTGTCAAC; p.(Ser726*) De novo M EIEE Yes
6 CDKL5 het duplication exons 6–11 De novo F EIEE Yes
7 CDKL5 het c.167_168del; p.(Thr56Asnfs*6) De novo F EIEE Yes
8 CDKL5 het c.965del; p.(Thr322Asnfs*28) Unknown F EIEE Yes
9 EHMT1 het c.1596del; p.(Thr533Profs*30) De novo M Developmental delay with seizures Yes
10 FOXG1 het c.256dup; p.(Gln86Profs*35) Unknown M EIEE Yes
11 FOXG1 het c.572T>G; p.(Met191Arg) From mosaic
mother
M Developmental delay with seizures Yes
12 FOXG1 het c.651C>G; p.(Tyr217*) De novo F Developmental delay No
13 FOXG1 het c.695A>G ; p.(Asn232Ser) De novo M Developmental delay with movement disorder No
14 FOXG1 het c.1188C>A; p.(Cys396*) De novo M Developmental delay with movement disorder No
15 GABRB3 het c.860C>T; p.(Thr287Ile) De novo M EIEE Yes
16 KCNQ2 het c.601C>T; p.(Arg201Cys) Unknown F EIEE Yes
17 KCNQ2 het c.637C>T; p.(Arg213Trp) Unknown F EIEE Yes
18 KCNQ2 het c.638G>A; p.(Arg213Gln) Unknown M EIEE Yes
19 KCNQ2 het c.1681C>T; p.(Pro561Ser) De novo M EIEE Yes
20* KCNQ2 het c.1741C>T; p.(Arg581*) From father M Neonatal seizures Yes
21* KCNQ2 het c.1741C>T; p.(Arg581*) From mother M Neonatal seizures Yes
22 KCNT1 het c.862G>A; p.(Gly288Ser) Unknown M Developmental delay with seizures Yes
23 KCNT1 het c.2687T>A; p.(Met896Lys) De novo F EIEE Yes
24* KCNT1 het c.2800G>A; p.(Ala934Thr) De novo M EIMFS Yes
25 LGI1 het c.1A>G p.(Met1?) Unknown M EIEE Yes
26 MBD5 het del chr2:149219863–149796844 including MBD5, EPC2,
KIF5C
De novo M Developmental delay Yes
27* MECP2 het exon 4 deletion De novo F Rett syndrome Yes
28* MECP2 het c.62+2_62+3del Unknown F Possible Rett syndrome No
29 MECP2 het c.844C>T; p.(Arg282*) Unknown F Developmental delay with seizures Yes
30* MECP2 het c.952C>T; p.(Arg318Cys) De novo F Rett syndrome No
31 MECP2 het c.1119_1147del; p.(Lys375Leufs*20) Unknown F Developmental delay with seizures Yes
32 PIGA het c.1064T>C; p.(Leu355Ser) De novo M EIEE Yes
33 PCDH19 het c.688G>A; p.(Asp230Asn) De novo F EIEE Yes
34 PCDH19 het c.707C>T; p.(Pro236Leu) De novo F EIEE Yes
35 PCDH19 het c.1882dup; p.(Arg628Profs*12) De novo F EIEE Yes
36* PRRT2 het c.649dup; p.(Arg217Profs*8) Unknown M Kinesogenic dyskinesia No
37 PRRT2 het c.1021T>C; p.(*341Argext*28) Unknown F Infantile seizure disorder Yes
38 SCN1A het c.302G>A; p.(Arg101Gln) De novo M EIEE Yes
39* SCN1A het c.2589+1_2589+2dup De novo M Dravet syndrome Yes
40 SCN1A het c.3851G>A; p.(Trp1284*) Unknown M Developmental delay with seizures Yes
41 SCN1A het c.4034C>T; p.(Pro1345Leu) De novo F EIMFS Yes
42 SCN1A het c.5010_5013del; p.(Phe1671Thrfs*8) De novo F EIEE Yes
43 SCN2A het c.2619C>G; p.(Ile873Met) De novo F EIEE with movement disorder Yes
44 SCN2A het c.2960G>T; (p.Ser987Ile) De novo F EIEE Yes
45 SCN2A het c.2995G>A; p.(Glu999Lys) De novo M EIEE Yes
46 SCN2A het c.2996A>T; p.(Glu999Val) De novo F EIEE Yes
47 SCN2A het c.3778A>G; p.(Lys1260Glu) and c.3778A>C; p.
(Lys1260Gln) mosaic
De novo M EIEE Yes
48 SCN2A het c.4303C>T; p.(Arg1435*) De novo M Autism with seizures Yes
49 SCN2A het c.4436A>C; p.(Gln1479Pro) De novo M EIEE Yes
50 SCN2A het c.4949T>C; p.(Leu1650Pro) De novo M EIEE Yes
51 SCN2A het c.5485C>T; p.(Leu1829Phe) De novo M EIEE Yes
52 SCN2A het c.5645G>A; p.(Arg1882Gln) De novo M EIEE Yes
53 SCN2A het c.5645G>A; p.(Arg1882Gln) De novo M EIEE Yes
54 SCN8A het c.1222G>A; p.(Ala408Thr) De novo M EIEE with movement disorder Yes
55 SCN8A het c.3943C>G; p.(Val1315Met) De novo F EIEE Yes
56 SCN8A het c.3967G>T; p.(Ala1323Ser) De novo M EIEE Yes
Continued
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of seizures from 9 months of age. These observations provide
further support for the proposed association of truncating muta-
tions with a milder seizure phenotype.16 This child was one of
two with only moderate developmental delay. A further child
(case 47) was apparently mosaic for two different de novo mis-
sense variants at the same residue: c.3778A>G; p.(Lys1260Glu)
and c.3778A>C; p.(Lys1260Gln). He had better seizure control
than the other children with SCN2A missense mutations and a
somewhat milder developmental phenotype, suggesting that one
or both of the variants may be attenuating the phenotype. Case
43, a profoundly developmentally delayed 14-year-old girl with
an SCN2A missense mutation, c.2619C>G; p.(Ile873Met), had
developed a generalised dystonia/dyskinetic movement disorder
and had an abnormal electroretinogram. These latter features
have not previously been reported to our knowledge with
SCN2A mutations. This child was also homozygous for the pre-
viously reported PNKP variant c.58C>T; p.(Pro20Ser).18 As dis-
cussed below, the contribution of this PNKP variant to her
phenotype is uncertain.
De novo monoallelic missense mutations in SCN8A are a
recently recognised cause of early-onset seizures with develop-
mental delay.19 20 We identiﬁed six such SCN8A mutations in
our series. All patients had early onset seizures, with a median
age of onset of 5 weeks of age (range 1 day to 5 months). In all
cases, the electroclinical phenotype was relatively non-speciﬁc.
In the ﬁve patients where we have data, the developmental
proﬁle is of severe or profound developmental delay. One child
had a very good response to phenytoin. Other clinical and
radiological manifestations may also be features of the condi-
tion. One child with profound developmental delay (case 54)
had a spastic dystonic movement disorder aged 9 years. This
child additionally had marked hypomyelination on MRI of the
brain.
Monoallelic mutations in KCNQ2 are a well-established cause
of early-onset seizures. Reported phenotypes vary from benign
familial neonatal seizures to a progressive pharmacoresistant
EIEE.21 22 We identiﬁed six KCNQ2 mutations. All had had sei-
zures from the neonatal period, with a median age of onset of
5 days. Two apparently unrelated individuals with benign neo-
natal seizures (cases 20 and 21) had the same truncating muta-
tion, c.1741C>T p.(Arg581*), which had been inherited from a
similarly affected parent.23 This mutation has been reported
previously in a similar context. We identiﬁed four de novo mis-
sense mutations in children with EIEE, including two with
mutations in the same codon, (c.637C>T; p.(Arg213Trp) and
c.638G>A; p.(Arg213Gln). These ﬁndings add weight to previ-
ously reported genotype–phenotype observations for KCNQ2,
with truncating mutations associated with the benign, inherited
phenotype and missense mutations affecting key residues with
the severe, sporadic phenotype. Cellular experiments indicate
that these latter mutations may have a dominant negative effect
on the function at a cellular level.22
De novo monoallelic mutations in KCNT1 are known to
cause early-onset seizures with developmental delay, with the
typical presentation of EIMFS.8 24 We identiﬁed three mis-
sense mutations in our series. While all presented with
early-onset focal seizures, in only one child (case 24) had
EIMFS been considered the working electroclinical diagnosis
prior to genetic testing. In a second (case 23), re-evaluation
of the phenotype in the light of the mutation conﬁrmed a
diagnosis of EIMFS.
De novo monoallelic mutations in CDKL5 are a well-
recognised cause of EIEE and severe, Rett-like developmental
delay.25 26 CDKL5 was mutated in ﬁve patients in our series
despite targeted diagnostic testing of the gene being available
and frequently requested by referring clinicians. The gene is
located on the X chromosome, and the majority of reports
describe de novo X-linked dominant mutations in females.25
One mutation-positive girl in our series (case 6) had previously
undergone diagnostic Sanger sequencing of the gene. This was
not capable of detecting her de novo multiexon intragenic
CDKL5 duplication identiﬁed by our exon-level microarray. Of
the remaining four CDKL5 mutation-positive cases, three were
male, highlighting the potential for under-recognition of this
gene as a cause of disease in males. All male CDKL5 mutation-
positive cases had been classiﬁed as having an EIEE, presenting
with seizures including infantile spasms aged 3 weeks and had
severe or profound developmental delay. Two of these had con-
ﬁrmed de novo mutations, one a truncation and one missense
mutation. The third (case 4), from whom parental samples are
not available, had a mutation previously reported in an affected
female.
Table 2 Continued
Case Gene Mutation Inheritance Gender Diagnosis at referral for testing Seizures
57 SCN8A het c.3979A>G; p.(Ile1327Val) De novo M EIEE Yes
58 SCN8A het c.5261T>C; p.(Phe1754Ser) De novo M EIEE Yes
59 SCN8A het c.5594T>C; p.(Leu1865Pro) De novo F EIEE Yes
60 SLC9A6 hemi c.608del p.(His203Leufs*10) De novo M Developmental delay with seizures and
movement disorder
Yes
61 SLC9A6 hemi c.1222_1226del; p.(His408Asnfs*2) De novo M EIEE Yes
62 STXBP1 het c.37+1G>A De novo F EIEE Yes
63 STXBP1 het c.842T>C; p.(Leu281Pro) De novo F Developmental delay with seizures Yes
64 STXBP1 het c.875G>A; p.(Arg292His) De novo M EIEE Yes
65 STXBP1 het c.1019_1020del; p.(Glu340Alafs*12) Unknown M Neonatal seizures including infantile spasms Yes
66 STXBP1 het c.1249+1G>T Unknown F EIEE Yes
67 TCF4 het c.826C>T; p.(Arg276*) De novo F Developmental delay No
68* TCF4 het c.1065C>G; p.(Se355Arg) De novo F Pitt–Hopkins syndrome No
69 TCF4 het c.1296+1G>T De novo M Developmental delay No
70 UBE3A het c.2572_2576dup; p.(Lys859Asnfs*7) Unknown F Developmental delay No
71* ZEB2 het c.2083C>T; p.(Arg695*) De novo M Mowat–Wilson syndrome No
*Cases in which referring clinician correctly nominated the causative gene at referral for testing.
EIEE, early infantile epileptic encephalopathy; EIMFS, epilepsy of infancy with migrating focal seizures; F, female; M, male.
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De novo monoallelic mutations in FOXG1 are typically asso-
ciated with early-onset seizures and severe, Rett-like develop-
mental delay.27 28 Other typical features include agenesis or
hypoplasia of the corpus callosum and a complex movement
disorder with dyskinesia, dystonia and chorea. We found
FOXG1 mutations in ﬁve individuals. Only two had seizures
and severe developmental delay (cases 10 and 12). The other
three mutation-positive cases had a strikingly milder phenotype.
Two manifested with moderate developmental delay with a
movement disorder but no seizures (cases 13 and 14). A third
(case 11) had mild developmental delay with (well-controlled)
seizures from 4 years. His mother was somatic mosaic for the
same missense mutation and was clinically unaffected. The
mutation was also present in the proband’s two similarly
affected sisters. We postulate that the phenotype of FOXG1 syn-
drome now includes a broader phenotypic spectrum including
milder cases with prominent movement disorders. Our data may
be in keeping with a genotype–phenotype correlation under-
lying this broadened phenotypic spectrum: of these milder
cases, one had a nonsense mutation late in the gene (case 14).
The other two had novel de novo missense variants (cases 11
and 13).
Hemizygous mutations in SLC9A6 cause an X-linked recessive
disorder known as Christianson syndrome.29 It was previously
referred to as X-linked Angelman syndrome and presents with
early-onset seizures, microcephaly, ataxia, dystonic movements
and evolving lower limb spasticity from the second decade. The
phenotype has been relatively consistent in the 15 families
reported to date.30 We identiﬁed mutations in SLC9A6 in two
boys in our series. Both had typical features of the condition,
with severe seizure disorders and severe or profound develop-
mental delay and dystonic movements. However, the gene had
not been considered the likely cause prior to testing in either
boy. As such, our ﬁndings both support the existing description
of the phenotype and emphasise the difﬁculty in recognising it.
Although both of the mutations we identiﬁed were de novo,
diagnosis of this X-linked recessive disorder can be associated
with a high risk or recurrence in further sons of a carrier
mother.
The large majority of mutations identiﬁed in our series were
de novo (51 of 54 from whom parental samples were available).
Partly, this reﬂects the fact that most of the genes analysed cause
disease by de novo monoallelic mutations. This considerably
aids analysis as rare variants of uncertain signiﬁcance can usually
be ruled out if they are inherited from an unaffected parent.
Inherited variants pose greater challenges in interpretation, par-
ticularly in the absence of a characteristic phenotype or clear-cut
prior evidence regarding the variant. Illustrative of these chal-
lenges are our ﬁndings in individuals with variants of uncertain
signiﬁcance in LGI1 and PNKP.
Inherited monoallelic loss-of-function mutations in LGI1
cause autosomal-dominant temporal lobe epilepsy.31 We identi-
ﬁed an initiation codon mutation in LGI1 in one child in our
series who presented with EIEE including infantile spasms and
subsequently frequent myoclonus and severe developmental
delay. There was no speciﬁc evidence of temporal lobe seizures
and no family history suggestive of temporal lobe epilepsy. His
parents declined testing for the LGI1 variant. While it is likely
that the variant predisposes to temporal lobe epilepsy, we con-
sider that it is unlikely to be the full explanation of his
phenotype.
Biallelic loss-of-function mutations in PNKP cause an
autosomal-recessive DNA repair disorder with a core phenotype
of EIEE, developmental delay and microcephaly. Seventeen
patients from nine families have been described to date.18 32 33
Six disease-causing variants have been reported, three frameshift
variants and three missense variants. A number of these variants
have been found in multiple families and/or have occurred in
trans with other clearly pathogenic variants, providing further
evidence of their pathogenicity. We identiﬁed one of the report-
edly pathogenic missense variants, c.58C>T; p.(Pro20Ser), in 9
of our 400 cases. Its frequent occurrence in our cohort and our
review of other available data lead us to be uncertain regarding
the pathogenicity of this variant.
PNKP c.58C>T has been reported in one previous case with
EIEE without data regarding head circumference.18 We identi-
ﬁed the variant in homozygous form in one child. This child,
case 43, also has a de novo monoallelic SCN2A mutation. She
had EIEE, profound developmental delay and microcephaly, fea-
tures that could be accounted for alone by the SCN2A mutation.
In eight others, from a range of ethnic backgrounds, we identi-
ﬁed the variant in heterozygous form without a second muta-
tion despite good quality sequence data across the gene. One of
these (case 40) also had an SCN1A nonsense mutation, consist-
ent with the presenting phenotype. We note that the variant has
an allele frequency of 0.0091 on the Exome Variant Server
(http://evs.gs.washington.edu/EVS/) and has an allele frequency
of 0.0076 on the ExAC database (http://www.exac.
broadinstitute.org). These ﬁgures are similar to that in our series
(0.0125). Taken together, these data suggest caution in interpret-
ing this variant as disease causing. It is likely that this is a
benign polymorphism.
The cost of gene panel analysis in a diagnostic setting is
now similar to that of Sanger sequencing a single gene.
Therefore, while targeted single-gene Sanger sequencing may
remain appropriate in some cases, for example, typical
SCN1A-related phenotypes, EIMFS (KCNT1), classical Rett
syndrome (MECP2) and some cases with other dysmorphic
syndromes, our data argue for the use of panel-based analysis
as the diagnostic genetic test of choice in the majority of indi-
viduals with early-onset seizure and severe developmental
delay disorders.
With time, we expect that panel analysis will evolve to use
data generated from sequencing larger numbers of genes, for
example, the whole exome or the clinical exome (all known
disease genes).10 34 Potential advantages include the ability to
add newly discovered genes without the need to redesign the
assay and to analyse larger panels of genes without running a
separate test. However, we currently ﬁnd the better sequence
coverage offered by a carefully designed and curated panel out-
weighs these potential beneﬁts in a diagnostic setting. We note
that the mutation detection rate we report in our early-onset
seizure cases is similar to that reported in studies employing
whole-exome sequencing in similar cohorts.35
While next-generation sequencing is a relatively new technol-
ogy, in many respects it is equally as robust as Sanger sequen-
cing. In some respects, it may be more robust, for example, in
the detection of low-level mosaic mutations.34 We identiﬁed
two mutations that had been missed despite previous Sanger
sequencing of the gene in question. An SCN1A mutation (case
39) had been missed due to a technical interpretation error, less
likely with more bioinformatics-driven interpretation pipelines
used in the analysis of next-generation sequencing data. A
MECP2 mutation (c.62+2_62+3delTG, in case 28) had also
been missed because it affected the ﬁrst exon of the gene, which
many diagnostic laboratories have not sequenced until recently
due to uncertainty about the most clinically relevant
transcript.36
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Like Sanger sequencing, next-generation sequencing remains
poor at detecting exon-level copy number abnormalities, par-
ticularly when samples are run in the relatively small batches
typical of a diagnostic setting.34 We, therefore, piloted the use
of an exon-level microarray targeting our gene panel in a subset
of our series. In our analysis of 33 cases without mutations on
panel sequencing, we identiﬁed three likely pathogenic copy
number abnormalities. Exon-level copy number analysis is also
valuable in individuals harbouring single mutations in
autosomal-recessive genes to search for second mutations and
assist in the interpretation of the signiﬁcance of sequence var-
iants. Until next-generation sequencing allows robust copy
number analysis, exon-level microarray will be a useful compo-
nent of gene panel analysis and we have now integrated it into
our standard analysis work stream.
In conclusion, our work demonstrates the signiﬁcant utility of
a gene panel approach in the diagnosis of patients with
early-onset epilepsy and severe developmental delay disorders,
particularly the former. It also broadens the phenotypic spec-
trum, provides insights into the genotype–phenotype relation-
ships of a number of the causative genes and emphasises the
importance of exon-level copy number testing in their analysis.
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